Pathology News
editor

About Editor

This author has not yet filled in any details.
So far Editor has created 933 blog entries.

February 2026

HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories

2026-02-24T14:21:55+00:00

Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced recognition by KLAS for customer-rated performance in the European digital pathology market, earning 94.9/100* and an ‘A’ grade* in each category. Best in KLAS® honors software organizations that excel at helping healthcare professionals deliver better patient care, based on a meticulous, independent analysis [...]

HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories2026-02-24T14:21:55+00:00

Tempus AI, Inc.: A Bull Case Theory

2026-02-24T12:10:21+00:00

We came across a bullish thesis on Tempus AI, Inc. on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on TEM. Tempus AI, Inc.'s share was trading at $64.57 as of January 28th. TEM’s trailing P/E was 41.53 according to Yahoo Finance. Tempus AI, Inc. (NASDAQ: TEM) operates at the forefront of precision [...]

Tempus AI, Inc.: A Bull Case Theory2026-02-24T12:10:21+00:00

AI-Enhanced Optical Coherence Photoacoustic Microscopy Revolutionizes 3D Cancer Model Imaging

2026-02-26T10:54:13+00:00

In the relentless pursuit of breakthroughs in cancer research and therapeutic development, three-dimensional cancer models such as organoids and spheroids have emerged as indispensable tools. These biomimetic constructs faithfully recapitulate the complex heterogeneity and intricate pathophysiology of tumors, all within a controlled in vitro environment. Despite their transformative potential, the technical challenge of non-invasively visualizing these 3D [...]

AI-Enhanced Optical Coherence Photoacoustic Microscopy Revolutionizes 3D Cancer Model Imaging2026-02-26T10:54:13+00:00

ASCO President Elect Talks Advancing Patient-Centered Care and Team-Based Innovation

2026-02-26T09:06:51+00:00

Author: Ariana Pelosci Fact checked by: Roman Fabbricatore Deb Schrag, MD, MPH, discusses her journey into GI oncology, the development of patient-reported outcome systems, and her vision for the upcoming ASCO presidency. Oncology has transitioned from a generalist field to one of immense sub-specialization, expanding to nearly 1000 different therapeutic options. For Deb Schrag, [...]

ASCO President Elect Talks Advancing Patient-Centered Care and Team-Based Innovation2026-02-26T09:06:51+00:00

Leica Biosystems Revolutionizes Histology Workflows with Global Launch of the Leica CM1950 Cryostat with DualEcoTec Cooling System

2026-02-24T12:10:12+00:00

Leica Biosystems, a Danaher company and a global leader in anatomic pathology solutions, is redefining histology workflows with the global launch  of the Leica CM1950 Cryostat with DualEcoTec Cooling System. This next-generation solution delivers superior performance, sustainability, and enhanced technician comfort— setting a new standard for cryostat technology. With up to 3x faster specimen cooling and [...]

Leica Biosystems Revolutionizes Histology Workflows with Global Launch of the Leica CM1950 Cryostat with DualEcoTec Cooling System2026-02-24T12:10:12+00:00

PathAI Expands AISight® Clinical Trials Platform with Launch of AIM-HI™ UC and IBDExplore™ for Standardized Histopathology Endpoints

2026-02-17T08:59:23+00:00

PathAI, a global leader in AI-powered pathology, today announced the strategic expansion of its support of inflammatory bowel disease clinical trials on the AISight® Clinical Trials Platform with the launch of IBDExplore to join AIM-HI UC. This launch marks a significant milestone for drug developers, making these advanced AI solutions immediately available for seamless integration into clinical [...]

PathAI Expands AISight® Clinical Trials Platform with Launch of AIM-HI™ UC and IBDExplore™ for Standardized Histopathology Endpoints2026-02-17T08:59:23+00:00

Why a Vendor-Agnostic IMS Is Key to a Future-Proof AI Strategy

2026-02-12T16:58:55+00:00

by Patrick Myles, MBACEO, PathPresenter As AI adoption accelerates in digital pathology, many institutions are facing a strategic decision that will shape their technology stack for years to come: how tightly should AI be coupled to the core imaging and workflow platform?At PathPresenter, we’ve taken a very deliberate position. On the AI side, we are [...]

Why a Vendor-Agnostic IMS Is Key to a Future-Proof AI Strategy2026-02-12T16:58:55+00:00

Labour Unveils Ambitious National Cancer Plan

2026-02-25T09:55:49+00:00

Under the new strategy, the government says three in four cancer patients in England could beat the disease.  Cancer has been the biggest killer in England for over a decade, causing around one in four deaths. Survival rates also lag behind multiple European countries, including Germany and Sweden. However, in a new plan announced on [...]

Labour Unveils Ambitious National Cancer Plan2026-02-25T09:55:49+00:00

Can AI Improve Veterinary Diagnostics and Academic Efficiency w/ Candice Chu, DVM, PhD, DACVP, Texas A&M University

2026-02-12T11:25:38+00:00

In this podcast session, I had the pleasure of sitting down with Candice Chu, DVM, PhD, DACVP, to discuss how artificial intelligence (AI) is transforming veterinary diagnostics and education. Candice, a clinical pathologist and educator at Texas A&M University, has been leading the way in integrating AI tools like ChatGPT into clinical pathology, helping to streamline workflows and enhance academic [...]

Can AI Improve Veterinary Diagnostics and Academic Efficiency w/ Candice Chu, DVM, PhD, DACVP, Texas A&M University2026-02-12T11:25:38+00:00

Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio

2026-02-12T12:02:06+00:00

Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI. The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026. These cancer types were [...]

Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio2026-02-12T12:02:06+00:00
Legal

Bioincyte Ltd is registered in the United Kingdom
under company number 13037659

Get in touch

© Copyright 2025, Bioincyte Ltd

Fields marked with an asterisk (*) are required.
By submitting you agree to our T&C and Privacy Policy

Go to Top